Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.74 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651649 | 0.90 | PTGS1 (0.76) | PTGS1KCNK9CA1CA2KCNK3 | |
| SCHEMBL29568808 | 0.89 | PTGS1 (0.79) | PTGS1KCNK9KCNK3RAB9ASMN1; SMN2 | |
| SCHEMBL8399784 | 0.89 | PTGS1 (0.79) | PTGS1KCNK9KCNK3RAB9ASMN1; SMN2 | |
| SCHEMBL5228698 | 0.89 | NR1H4 (0.77) | PTGS1KCNK9SMN1; SMN2NR1H4TP53 | |
| SCHEMBL21588759 | 0.88 | PTGS1 (0.72) | PTGS1KCNK9CA1CA2KCNK3 | |
| SCHEMBL15149769 | 0.86 | PTGS1 (0.56) | PTGS1KCNK9CA1CA2KCNK3 | |
| SCHEMBL2344887 | 0.86 | SMN1; SMN2 (0.56) | PTGS1KCNK9CA1CA2RAB9A | |
| SCHEMBL29672230 | 0.85 | PTGS1 (0.74) | PTGS1KCNK9CA1CA2KCNK3 | |
| SCHEMBL927121 | 0.85 | PTGS1 (0.74) | PTGS1KCNK9CA1CA2KCNK3 | |
| SCHEMBL15650654 | 0.85 | PTGS1 (0.65) | PTGS1KCNK9CA1CA2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| WO-2015151006-A1 | SUBSTITUTED PURINE COMPOUNDS AS BTK INHIBITORS | LUPIN LIMITED (IN) | 2015-10-08 | — | — | WO | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-0358118-B1 | Phenylamides - process for their preparation as well as a drug containing those compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5135949-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0358118-A1 | Phenylamides - process for their preparation as well as a drug containing those compounds | Roche Diagnostics GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PTGS1 2100/4885KCNK9 404/4885CA1 4834/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PTGS1 2100/4885KCNK9 404/4885CA1 4834/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PTGS1 1996/4885KCNK9 439/4885CA1 4820/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PTGS1 1996/4885KCNK9 439/4885CA1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.